NSEAgreements2 Sept 2026 · 2 Sept 2026, 07:18 pm

Agreements

Coromandel International Limited · COROMANDEL

✦ AI SummaryRelated Party

Coromandel International Limited has informed the Exchange about an agreement for conversion of loan to equity with Coromandel Chemicals Limited, a wholly owned subsidiary, at an issue price of Rs. 39.95 per equity share.

Analysis Scores

Earnings Impact2/10
Growth Catalyst1/10
Governance Concern5/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Coromandel International Limited has informed the Exchange about Agreements

Attachments (1)

📄

COROMANDELINT_02092026191508_CIL_SELetter_Sep_2026_SD.pdf

pdf

Download →
View document text
Coromandel International Limited Corporate Office: Olympia Terraces, 15B SP, SIDCO Industrial Estate, Guindy, Chennai – 600032, Tamil Nadu, India CIN: L24120TG1961PLC000892 Tel: 91-44-42525300 E-mail: mail@coromandel.murugappa.com Website: www.coromandel.biz Ref. No.: 2026-27/037 September 2, 2026 National Stock Exchange of India Limited BSE Limited, Exchange Plaza, 5th Floor, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Dalal Street, Bandra (E), Mumbai 400 051 Mumbai 400 001. Symbol: COROMANDEL S c r i p C o d e : 5 0 6 3 9 5 Dear Sirs/Madam, Sub : Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended ("SEBI Listing Regulations") In furtherance to our letter ref no. 2026-27/026 dated July 23, 2026 and pursuant to Regulation 30 and other applicable provisions of the SEBI Listing Regulations, we wish to inform that the Company had executed an agreement for conversion with the Coromandel Chemicals Limited for conversion of loan including accrued interest amounting to Rs. 108.07 Crores to equity shares of face value of Rs. 10/- each of Coromandel Chemicals Limited, a wholly owned subsidiary of the Company, at an issue price of Rs. 39.95/- per equity share (including premium). The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed as Annexure A. We request you to acknowledge and take it on your record. Thanking you, Yours truly, For Coromandel International Limited B Shanmugasundaram Company Secretary & Compliance officer Enclosure: As Above. Coromandel International Limited Corporate Office: Olympia Terraces, 15B SP, SIDCO Industrial Estate, Guindy, Chennai – 600032, Tamil Nadu, India CIN: L24120TG1961PLC000892 Tel: 91-44-42525300 E-mail: mail@coromandel.murugappa.com Website: www.coromandel.biz Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 Name(s) of parties with whom the Coromandel International Limited and agreement is entered; Coromandel Chemicals Limited (Wholly Owned subsidiary The Company proposes to convert the loan Purpose of entering into the agreement including accrued interest amount of Rs. 108.07 Crores into equity vide Agreement for conversion agreement dated September 2, 2026 Size of agreement Rs. 108.07 Crores Shareholding, if any, in the entity with The company owns 100% shareholding in whom the agreement is executed. Coromandel Chemicals Limited Significant terms of the agreement (in Conversion of Loan to Equity brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc. Whether the said parties are related to Yes, Coromandel Chemicals Limited is a wholly promoter/promoter group/ group owned subsidiary of the Company companies in any manner. If yes, nature of relationship Whether the transaction would fall Yes, The Company at its Audit Committee and within related party transactions? If yes, Board Meeting held on July 23, 2026 approved the whether the same is done at “arm’s said related party transaction. The Transaction is length undertaken on an arm’s length basis In case of issuance of shares to the 2,70,52,132 Equity shares of face value of Rs. 10/- parties, details of issue price, class of each of Coromandel Chemicals Limited, a wholly shares issued owned subsidiary of the Company, at an issue price of Rs. 39.95/- per equity share (including premium, if any) is issued equivalent to Rs. 108.07 Crores In case of loan agreements, details of S.No. Particulars Details lender/borrower, nature of the loan, 1 Lender Coromandel total amount of loan granted/taken, International total amount outstanding, date of Limited execution of the loan 2 Borrower Coromandel agreement/sanction letter, details of Chemicals the security provided to the lenders / by Limited the borrowers for such loan or in case 3 Nature of Loan Unsecured outstanding loans lent to a party or loan Coromandel International Limited Corporate Office: Olympia Terraces, 15B SP, SIDCO Industrial Estate, Guindy, Chennai – 600032, Tamil Nadu, India CIN: L24120TG1961PLC000892 Tel: 91-44-42525300 E-mail: mail@coromandel.murugappa.com borrowed from a party become material 4 Date of exW ee cb us tit ie o: n w ww.cor 1omst an Dd ee cl. ebi mz ber on a cumulative basis; 2025 5 Security provided, if Nil 6 Amount of Loan Rs. 108.07 outstanding as on Crore date of disclosure (Amount of Loan outstanding including accrued interest as on 30th June, 2026) Any other disclosures related to such No nominee director has been appointed through agreements, viz., details of nominee on proposed agreement. No conflict of interest arises the board of directors of the listed other than the related party relationship disclosed entity, potential conflict of interest above. arising out of such agreements, etc.; In case of termination or amendment of Not Applicable agreement, listed entity shall disclose additional details to the stock exchange(s): i. name of parties to the agreement; ii. nature of the agreement; iii. date of execution of the agreement; iv. details of amendment and impact thereof or reasons of termination and impact thereof.